FIELD: medicine. SUBSTANCE: invention relates to treatment of mammals with bacterial infection. After eating an effective dose of azithromycin as an oral drug is administrated to mammals. Solubility of azithromycin is 90% for 30 min when amount of drug containing 200 mg azithromycin is tested by method VSP-711 in an advice VSP-2 for dissolving under the rigid conditions that correspond the following indices: 90 ml sodium-phosphate buffer, pH 6.0, at 37 C using blade mixer working at 100 rev/min, and/or value AIS pich/AIS gol is at least 0.80 and at lower 90% limit of reliability, at least 0.75. Medicinal form proposed for treatment does not exhibit negative alimentary effect. EFFECT: improved method of treatment. 28 cl, 15 tbl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
AZALIDE-CONTAINING PHARMACEUTICAL COMPOSITION EXHIBITING A DECREASED BITTER TASTE AND A METHOD OF TREATMENT OF MAMMALIAN WITH BACTERIAL INFECTION (VARIANTS) | 1993 |
|
RU2126257C1 |
METHODS FOR AZITROMICINE WET GRANULATION | 2002 |
|
RU2283651C2 |
DRY GRANULATED AZITHROMICINE COMPOSITIONS | 2003 |
|
RU2283092C2 |
MEDICINAL CONTROLLED-RELEASING FORMS OF AZITHROMYCIN | 1995 |
|
RU2130311C1 |
TOSYLATE SALT OF TRANS-N-ISOBUTYL-3-FLUORO-3-[3-FLUORO-4-(PYRROLIDIN-1-YLMETHYL)PHENYL]CYCLOBUTANE CARBOXAMIDE | 2008 |
|
RU2451016C2 |
COMPOSITION SIMETHICONE/ANHYDROUS CALCIUM PHOSPHATE | 1998 |
|
RU2216317C2 |
USE OF INDOLE DERIVATIVES AS 5-HTI-AGONISTS | 1994 |
|
RU2132683C1 |
TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS | 2014 |
|
RU2674345C2 |
ORAL DOSAGE FORMS OF TOFACITINIB WITH CONTINUOUS RELEASE | 2014 |
|
RU2790166C2 |
TOSYLATE SALT OF THERAPEUTIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | 2008 |
|
RU2430099C2 |
Authors
Dates
1999-04-20—Published
1995-04-28—Filed